果糖-1。6-二磷酸醛缩酶(FDA)检测试剂盒,货号:BC2270-50管/48样
市场价: | ¥2160.0 | |
价格: |
|
|
品牌: | solarbio | |
规格: | 50管/48样 |
产品详情
说明书下载
参考文献
|
果糖-1。6-二磷酸醛缩酶(FDA)检测试剂盒,货号:BC2270-50管/48样
市场价: | ¥2160.0 | |
价格: |
|
|
品牌: | solarbio | |
规格: | 50管/48样 |
产品详情
说明书下载
参考文献
|
土壤FDA水解酶活性检测试剂盒,货号:BC0485-100管/48样
市场价: | ¥1200.0 | |
价格: |
|
|
品牌: | solarbio | |
规格: | 100管/48样 |
产品详情
说明书下载
参考文献
|
FDA认证化合物库化合物库-Wako富士胶片和光
供货周期 | 一个月 | 应用领域 | 生物产业 |
---|
药物再定位或用于新的疾病治疗是药物研发非常重要的一部分,使用这种方法已经研发出好几种药品(比如Viagra 和Rogaine)。高内涵筛选,新型生物标记物和非侵入性成像技术都为探索认证化合物创造了机遇。SCREEN-WELL® FDA 认证化合物库可应用于临床研究,其所有化合物都具有已知生物活性、安全性和生物利用度等特性,可加速药物研发和优化。
SCREEN-WELL® FDA 批准药物 化合物库
SCREEN-WELL® FDA approved drug library
◆原理
药物再定位或用于新的疾病治疗是药物研发非常重要的一部分,使用这种方法已经研发出好几种药品(比如Viagra 和Rogaine)。高内涵筛选,新型生物标记物和非侵入性成像技术都为探索认证化合物创造了机遇。SCREEN-WELL® FDA 认证化合物库可应用于临床研究,其所有化合物都具有已知生物活性、安全性和生物利用度等特性,可加速药物研发和优化。该化合物库不含有无关的化合物,比如除草剂、杀虫剂、防晒剂和细胞毒素等。为您提供大量具有生物活性和药物类似的化合物。该化合物库是您开展药物筛选的良好开端。为了方便您进一步的研究,大多数化合物都可单独出售。
◆优点・特色
● 用于心脏病学、神经精神病学、免疫学和肿瘤学等相关疾病的药物研发。
● 在以前FDA 认证化合物库的基础上增加了100 多种化合物
● 提供100% 已知生物活性和较大程度药物类似化合物
● 包含近期得到FDA 认证的化合物
● 每一种化合物都附有详细的产品说明
◆案例・应用
药物repositioning或者repurposing(重利用)是药物研发进程的重要部分,该技术已经发现了几种药(比如,万.艾可和落健)。高通量筛选,新的生物标记物,非入侵式影像技术可用于批准药物鉴定(批准药物的新鉴定方法)。所有的SCREEN-WELL® FDA approved drug library V2化合物都是已知的,FDA已经批准并且在临床使用。已经鉴定了生物活性,安全性和生物利用度,可以明显加速研发和优化的速度。该化合物库不含有类似化合物库中的无关化合物,比如除草剂,农药、遮光剂和细胞毒素。该化合物提供了丰富生物活性的化合物,与药物类似的化合物商品。这个库的候选化合物是药物优化进程的选择之一。
运用:高通量筛选。
试剂盒组分:超过780种化合物。具有多种化学和药理特性。
浓度:10 mM(DMSO溶解,部分是用不含核酸酶的水溶解)
保存:-80℃
◆产品列表
产品编号 | 产品名称 | 规格 |
BML-2842-0500 | FDA approved drug library (10mM) | 500 µL/well、100 µL/well |
BML-2842-0100 | FDA approved drug library (10mM) | 500 µL/well、100 µL/well |
BML-2841-0500 | FDA approved drug library | 500 µL/well、100 µL/well |
BML-2841-0100 | FDA approved drug library | 500 µL/well、100 µL/well |
土壤FDA水解酶活性检测试剂盒,货号:BC0480-50管/24样
市场价: | ¥720.0 | |
价格: |
|
|
品牌: | solarbio | |
规格: | 50管/24样 |
产品详情
说明书下载
参考文献
|
ENZO Screen-Well ® FDA approved Drug library V2
ENZO在鉴定、合成、商业化生产生物活性化合物方面具有丰富的经验,其提供的Screen-Well®化合物库系列产品,可为化合物筛选提供简单、快捷的分析手段。化合物库中包含多类抑制剂、激活剂、诱导剂等3000多种小分子,产品说明书中提供完整的化合物活性描述、物理性质、结构组成等信息。
产品名称 |
产品编号 |
Screen-Well ® Histaminergic ligand library (100 ul/well) |
BML-2816-0100 |
Screen-Well ® Adrenergic ligand library (100 ul/well) |
BML-2811-0100 |
Screen-Well ® Metabotropic glutamatergic ligand library (100 ul/well) |
BML-2818-0100 |
Screen-Well ® Dopaminergic ligand library (100 ul/well) |
BML-2812-0100 |
Screen-Well ® Phosphatase inhibitor library (100 ul/well) |
BML-2834-0100 |
Screen-Well ® REDOX library 100 ul/well |
BML-2835-0100 |
Screen-Well ® Fatty Acid library (100 ul/well) |
BML-2803-0100 |
Screen-Well ® Wnt Pathway library 100 ul/well |
BML-2838-0100 |
Screen-Well ® Purinergic ligand library (100 ul/well) |
BML-2820-0100 |
Screen-Well ® Fatty acid library (500 ul/well) |
BML-2803-0500 |
Screen-Well ® Nuclear Receptor ligand library (100 ul/well) |
BML-2802-0100 |
Screen-Well ® Hematopoietic library (100ul per well) |
BML-2852-0100 |
Screen-Well ® Autophagy library |
BML-2837-0500 |
Screen-Well ® Cardiotoxicity library (100ul per well) |
BML-2850-0100 |
Screen-Well ® Endocannabinoid library (500 ul/well) |
BML-2801-0500 |
Screen-Well ® Orphan ligand library (500 ul/well) |
BML-2825-0500 |
Screen-Well ® Epigenetics library (500 ul/well) |
BML-2836-0500 |
Screen-Well ® Cholinergic ligand library (100 ul/well) |
BML-2815-0100 |
Screen-Well ® Epigenetics library (100 ul/well) |
BML-2836-0100 |
Screen-Well ® Autophagy library |
BML-2837-0100 |
Screen-Well ® Kinase inhibitor library (100 ul/well) |
BML-2832-0100 |
Screen-Well ® Heptatoxicity library (100ul per well) |
BML-2851-0100 |
Screen-Well ® Kinase inhibitor library (500 ul/well) |
BML-2832-0500 |
Screen-Well ® Ion Channel ligand library (500 ul/well) |
BML-2805-0500 |
Screen-Well ® Hematopoietic library (500ul per well) |
BML-2852-0500 |
Screen-Well ® Phosphatase inhibitor library (500 ul/well) |
BML-2834-0500 |
Screen-Well ® Cardiotoxicity library (500ul per well) |
BML-2850-0500 |
Screen-Well ® Neurotransmitter library (10 plate set) (100ul/well) |
BML-2810-0100 |
Screen-Well ® Wnt Pathway library 500 ul/well |
BML-2838-0500 |
Screen-Well ® Bioactive Lipid library (500 ul/well) |
BML-2800-0500 |
Screen-Well ® Nuclear Receptor ligand library (500 ul/well) |
BML-2802-0500 |
Screen-Well ® FDA approved Drug library V2 |
BML-2843-0100 |
Screen-Well ® Endocannabinoid library (100 ul/well) |
BML-2801-0100 |
Screen-Well ® REDOX library (500 ul/well) |
BML-2835-0500 |
Screen-Well ® ICCB known bioactives library (100 ul/well) |
BML-2840-0100 |
Screen-Well ® Protease inhibitor library (100 ul/well) |
BML-2833-0100 |
Screen-Well ® Protease inhibitor library (500 ul/well) |
BML-2833-0500 |
Screen-Well ® Natural Product library (100 ul/well) |
BML-2865-0100 |
Screen-Well ® Natural Product library 500 ul/well |
BML-2865-0500 |
Screen-Well ® Ion Channel ligand library (100 ul per well) |
BML-2805-0100 |
Screen-Well ® Bioactive Lipid library (100 ul/well) |
BML-2800-0100 |
Screen-Well ® Serotonergic ligand library (100 ul/well) |
BML-2813-0100 |
Screen-Well ® Neurotransmitter library (10 plate set) (500 ul/well) |
BML-2810-0500 |
Screen-Well ® Heptatoxicity library (500ul per well) |
BML-2851-0500 |
Screen-Well ® GABAergic ligand library (100 ul/well) |
BML-2819-0100 |
Screen-Well ® Ionotropic glutamatergic ligand library (100 ul/well) |
BML-2817-0100 |
Screen-Well ® Nephrotoxicity Library (100ul/well) |
ENZ-LIB100-0100 |
Screen-Well ® Serotonergic ligand library (500 ul/well) |
BML-2813-0500 |
Screen-Well ® Opioid ligand library (500 ul/well) |
BML-2814-0500 |
Screen-Well ® Purinergic ligand library (500 ul/well) |
BML-2820-0500 |
Screen-Well ® Dopaminergic ligand library (500 ul/well) |
BML-2812-0500 |
Screen-Well ® Cholinergic ligand library (500 ul/well) |
BML-2815-0500 |
Screen-Well ® Metabotropic Glutamatergic ligand library (500 ul/well) |
BML-2818-0500 |
Screen-Well ® Adrenergic ligand library (500 ul/well) |
BML-2811-0500 |
Screen-Well ® GABAergic ligand library (500 ul/well) |
BML-2819-0500 |
Screen-Well ® Ionotropic Glutamatergic ligand library (500 ul/well) |
BML-2817-0500 |
Screen-Well ® Opioid ligand library (100 ul/well) |
BML-2814-0100 |
Screen-Well ® Histaminergic ligand library (500 ul/well) |
BML-2816-0500 |
Screen-Well ® Myotoxicity library |
ENZ-LIB101-0100 |
文献引用
—————————————————————————————————————————–
1. Identification of trichlormethiazide as a Mdr1a/b gene expression enhancer via a dual secretion-based promoter assay: S. Schulze, et al.;
Pharma. Res. Per. 3, e00109 (2015), Application(s): Cell Culture, Full Text
2. 3D high-content screening for the identification of compounds that target cells in dormant tumor spheroid regions: C. Wenzel, et al.; Exp.
Cell Res. 15, 323 (2014), Abstract;
3. A yeast-based assay identifies drugs that interfere with Epstein-Barr virus immune evasion: C. Voisset, et al.; Dis. Model Mech.7, 435 (2014),
Abstract; Full Text
4. Antifungal Application of Nonantifungal Drugs: M. Stylianou, et al.; Antimicrob. Agents Chemother. 58, 1055 (2014),Application(s): In vitro
susceptibility testing of C. albicans strain SC5314, Abstract; Full Text
5. Fluoxetine prevents dystrophic changes in a zebrafish model of Duchenne muscular dystrophy : T.A. Waugh, et al.; Hum. Mol. Genet. 23, 4651 (2014),
Application(s): Drug screening in zebrafish model of Duchenne muscular dystrophy, Abstract;
6. Host-Directed Antimicrobial Drugs with Broad-Spectrum Efficacy against Intracellular Bacterial Pathogens: D.M. Czyz, et al. ; mBio 5, e01534 (2014),
Application(s): Screening of FDA-approved drugs for compounds that block the intracellular growth ofC. burnetii in THP-1 cells, Abstract; Full Text
7. Fluorescent dye cocktail for multiplex drug-site mapping on human serum albumin: J.C. Er, et al.; ACS Comb. Sci. 15, 452 (2013), Abstract;
8. Miniature short hairpin RNA screens to characterize antiproliferative drugs: S. Kittanakom, et al.; G3 (Bethesda) 3, 1375 (2013),Application(s):
Screening of A549 cells, Abstract; Full Text
9. Systematic evaluation of 640 FDA drugs for their effect on CD4⁺Foxp3⁺ regulatory T cells using a novel cell-based high throughput screening assay:
R. Mao, et al.; Biochem. Pharmacol. 85, 1513 (2013), Abstract;
10. The toll-like receptor agonist imiquimod is active against prions: N. Oumata, et al.; PLoS One 8, e72112 (2013), Abstract; Full Text
11. Identification of Modulators of Hair Cell Regeneration in the Zebrafish Lateral Line: P. Namdara,et al. ; J. Neurosci. 32, 3516 (2012), Application (s):
Chemical screen for modulators of hair cell regeneration using zebrafish lateral line neuromasts as a platform, Abstract; Full Text
12. Systematic identification of synergistic drug pairs targeting HIV: X. Tan, et al.; Nat. Biotechnol. 30, 1125 (2012), Abstract;
植物叶绿体中果糖-1,6-二磷酸醛缩酶(FDA)检测试剂盒 UV板 微量法,FDA Assay Kit,货号:BC2005-100管/96样
市场价: | ¥4500.0 | |
价格: |
|
|
品牌: | solarbio | |
规格: | 100管/96样 |
产品详情
说明书下载
参考文献
|
植物叶绿体中果糖1,6-二磷酸醛缩酶(Fructose 1,6 bisphosphate aldolase,FDA)试剂盒,货号:BC2000-50管/48样
市场价: | ¥2340.0 | |
价格: |
|
|
品牌: | solarbio | |
规格: | 50管/48样 |
产品详情
说明书下载
参考文献
|
果糖-1,6-二磷酸醛缩酶(FDA)检测试剂盒 UV板 微量法,FDA Assay Kit,货号:BC2275- 100管/96样
市场价: | ¥4140.0 | |
价格: |
|
|
品牌: | solarbio | |
规格: | 100管/96样 |
产品详情
说明书下载
参考文献
|